Published online Jun 18, 2015. doi: 10.4254/wjh.v7.i11.1494
Peer-review started: March 2, 2015
First decision: April 10, 2015
Revised: April 19, 2015
Accepted: May 7, 2015
Article in press: May 8, 2015
Published online: June 18, 2015
Processing time: 107 Days and 19 Hours
Shortage of appropriate donor grafts is the foremost current problem in organ transplantation. As a logical consequence, waiting times have extended and pretransplant mortality rates were significantly increasing. The implementation of a priority-based liver allocation system using the model of end-stage liver disease (MELD) score helped to reduce waiting list mortality in liver transplantation (LT). However, due to an escalating organ scarcity, pre-LT MELD scores have significantly increased and liver recipients became more complex in recent years. This has finally led to posttransplant decreasing survival rates, attributed mainly to elevated rates of infectious and immunologic complications. To meet this challenging development, an increasing number of extended criteria donor grafts are currently accepted, which may, however, aggravate the patients’ infectious and immunologic risk profiles. The administration of intravenous immunoglobulins (IVIg) is an established treatment in patients with immune deficiencies and other antibody-mediated diseases. In addition, IVIg was shown to be useful in treatment of several disorders caused by deterioration of the cellular immune system. It proved to be effective in preventing hyperacute rejection in highly sensitized kidney and heart transplants. In the liver transplant setting, the administration of specific Ig against hepatitis B virus is current standard in post-LT antiviral prophylaxis. The mechanisms of action of IVIg are complex and not fully understood. However, there is increasing experimental and clinical evidence that IVIg has an immuno-balancing impact by a combination of immuno-supporting and immuno-suppressive properties. It may be suggested that, especially in the context of a worsening organ shortage with all resulting clinical implications, liver transplant patients should benefit from immuno-regulatory capabilities of IVIg. In this review, perspectives of immune modulation by IVIg and impact on outcome in liver transplant patients are described.
Core tip: In times of an escalating organ scarcity, decreasing posttransplant survival rates following liver transplantation have been reported. Predominantly infectious and immunologic complications were identified to account for this recent outcome deterioration. Therefore, balancing the recipients’ immune system is currently discussed as useful approach to improve prognosis. Intravenous immunoglobulins (IVIg) are thought to provide favorable immuno-regulatory capabilities. This paper summarizes the current available clinical data that indicate beneficial immuno-modulatory properties of IVIg in liver transplant patients.